Exjade

Exjade is a brand name of deferasirox, approved by the FDA in the following formulation(s):

EXJADE (deferasirox - tablet, for suspension; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: November 2, 2005
  
  Strength(s): 125MG, 250MG, 500MG ^[RLD]

Has a generic version of Exjade been approved?

No. There is currently no therapeutically equivalent version of Exjade available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exjade. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
  Patent 6,465,504
  Issued: October 15, 2002
  Inventor(s): René ; Lattmann & Pierre; Acklin
  Assignee(s): Novartis AG
  The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.
  
  Patent expiration dates:
  
  
  • April 5, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
  Patent 6,596,750
  Issued: July 22, 2003
  Inventor(s): René ; Lattmann & Pierre; Acklin
  Assignee(s): Novartis AG
  The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.
  
  Patent expiration dates:
  
  
  • June 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING CHRONIC IRON OVERLOAD
    ✓ 
    Drug substance
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 2, 2010 - NEW CHEMICAL ENTITY
  
  
  • November 2, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Exjade Consumer Information (Drugs.com)
• Exjade Consumer Information (Wolters Kluwer)
• Exjade Consumer Information (Cerner Multum)
• Exjade Advanced Consumer Information (Micromedex)
• Exjade AHFS DI Monographs (ASHP)
• Deferasirox Consumer Information (Wolters Kluwer)
• Deferasirox Consumer Information (Cerner Multum)
• Deferasirox Advanced Consumer Information (Micromedex)
• Deferasirox AHFS DI Monographs (ASHP)